Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
  • 69

  • 32

  • 16

  • 10

  • 10

  • 9

  • 7

  • 6

  • 6

  • 5

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Country of Funder
Start Year
Active Year
Similar Projects for


Understanding barriers to single-dose intravesical chemotherapy in non-muscle invasive bladder cancer

Funder: National Cancer Institute

Funding period
USD 575 K
Funding amount
Project Summary/Abstract Randomized trials utilizing a single dose of intraoperative intravesical chemotherapy following transurethral bladder tumor resection have consistently demonstrated a reduction in bladder cancer recurrences. However, existing data suggests intraoperative intravesical chemotherapy is used infrequently, sometimes occurs in the wrong patients, and occurs only in a minority of cases. In this context, the candidate (Dr. Kelly Clinton Cary) seeks to determine the barriers to intraoperative intravesical chemotherapy and how to effectively develop and implement interventions to increase translation of this best available evidence into clinical practice. During the period of support, he will pursue additional didactic instruction in several disciplines, including graduate-level courses in qualitative research methods and implementation science, as well as conjoint analysis. He will also have ample opportunities for mentored, project-based learning, including the hands-on application of cognitive task analysis interview techniques, advanced statistical modeling with conjoint analysis, and implementation strategy design. The research plan has three specific aims: Aim 1. To determine the barriers and facilitators to intraoperative intravesical chemotherapy utilization in non-muscle invasive bladder cancer. The candidate will conduct semi-structured interviews with key stakeholders directly or indirectly involved in the process of delivering intraoperative intravesical chemotherapy using the interview technique of cognitive task analysis. Key stakeholders will involve five distinct groups: 1) urologists, 2) patients, 3) pharmacists, 4) nurses, 5) administrative leaders. He hypothesizes it will be possible to identify several barriers and facilitators through the interview process. Aim 2. To assess the relative importance of individual barriers and facilitators to intravesical chemotherapy utilization. The candidate will perform a conjoint analysis study using clinical vignettes to identify which barriers are most important in utilizing intravesical chemotherapy. This analysis will use a marketing research technique to determine which barriers and facilitators are most influential resulting in a rating of individual barriers. He hypothesizes that not all barriers and clinical factors are considered equally important or influential. Aim 3. To develop intervention and implementation strategies to address the most important barriers to intravesical chemotherapy utilization. Using implementation science methods, intervention(s) and implementation strategies targeting the most important barriers and facilitators will be developed and iteratively improved using key stakeholders' input. He hypothesizes that well designed intervention and implementation strategies tailored to important barriers and facilitators with iterative input from key stakeholders can be developed to improve the delivery of evidence-based medicine. Completion of the proposed research will create a framework for answering the questions surrounding barriers in care and have an immediate impact for patients with bladder cancer in developing and implementing an intervention to reduce cancer recurrences.

USD 85.6 M
Aggregated funding amount
USD 563 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer


USD 703,400
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

2019 - 2023
Project list item
Implementing Risk-aligned Bladder Cancer Surveillance

United States Department of Veterans Affairs to FLORIAN R SCHROECK

2019 - 2023
Project list item
Transdifferentiation of fibroblasts to urothelial progenitors for definitive urothelial replacement therapy in non-muscle invasive bladder cancer

Bladder Cancer Advocacy Network to Philip A Beachy, Kris Butalid Prado

USD 300,000
2019 - 2021
Project list item
[Efficacy and toxicity of bladder instillation of anti-tumor peptide for inhibition of bladder tumor in mice] - Original in Japanese

Japan Society for the Promotion of Science to Toru SHIMAZUI, Kazuhiro YOSHIKAWA, Takahiro Kojima, Hiroyuki NISHIYAMA

USD 39,492
2019 - 2022
Project list item
[Studies on a novel immunotherapy for bladder cancer by NAD+] - Original in Japanese

Japan Society for the Promotion of Science to 博史 上原, Kazumasa Komua, Haruhito AZUMA

USD 39,508
2019 - 2024
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 372,404
2019 - 2021
Project list item
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research

National Cancer Institute to ANIKET A KAWATKAR, KIM N DANFORTH

USD 382,751
2019 - 2021
Project list item
Clonal evolution and molecular stratification of urothelial carcinoma in situ of the urinary bladder

German Research Foundation to Stefan Garczyk, Nadine Gaisa

2019 -
Project list item
The role of a new molecular driver in bladder cancer

National Cancer Institute to DALEY MORERA

USD 90,032
2018 - 2021
Project list item
A co-clinical trial of chemotherapy response in bladder cancer using patient-derived tumor organoids

V Foundation for Cancer Research to Michael M Shen

USD 600,000
2018 - 2021
load more...